Table 1.
Study Description and Incidence of Atrial Fibrillation in STEMI Patients
| Study | Pts, n | Design | Inclusion criteria | Treatment | Trial Period | Any AF, % | Prior AF, % | New-Onset/In- Hospital AF, % |
|---|---|---|---|---|---|---|---|---|
| GUSTO I2 | 40891 | RCT | STEMI | Thrombolysis streptokinase vs alteplase | 1 year | 10.4% | 2.5% | 7.9% |
| GUSTO III8 | 13858 | RCT | STEMI | Thrombolysis alteplase vs reteplase | 1 year | - | - | 6.5% |
| GISSI9 | 17944 | RCT | STEMI | Thrombolysis 72% lisinopril/lisinopril+nitrates/nitrates | 4 years | - | - | 7.8% |
| TRACE10 | 6776 | RCT Pre-enrolment | STEMI LV dysfunction | Thrombolysis 75% of patients | 5 years | - | 3.9% | 21% |
| OPTIMAAL11 | 5477 | RCT | STEMI HF and LV dysfunction (EF<40% or LVED>=65) | Thrombolytics- 54.4% Captopril vs losartan | 3 years | - | 12% | 7.2% |
| VALIANT12 | 14703 | RCT | STEMI Radiological or clinical HF and/or LV dysfunction | Thrombolytics 35.1%, primary PCI 14.8% Captorpil, valsartan or both | 3 years | - | 2.3% | 12.3% |
| OACIS4 | 2475 | Observational cohort study | STEMI | Primary PCI | 1 year | 12% | 4.3% | 7.7% |
| APEX-MI15 | 5745 | Observational cohort | STEMI | Primary PCI, dual and triple antithrombotic therapy | 11% | 4.8% | 6.3% |